MedPath

Xeltis Secures €12.5 Million to Advance aXess Vascular Graft Development

• Xeltis has secured an additional €12.5 million from the European Innovation Council (EIC) Fund, bringing the total raised to €44.5 million, to support its cardiovascular implant developments. • The funding will primarily support the first-in-human (FIH) trial of aXess vascular graft for chronic kidney disease patients needing hemodialysis and an ongoing pivotal trial across Europe. • Xeltis' endogenous tissue restoration platform uses a polymer implant to regenerate the patient's own tissue, creating living and long-lasting vessels before being absorbed. • Six-month data from the aXess-FIH study were presented at the Vascular Access Society Congress, highlighting the progress of the implantable blood vessel for hemodialysis vascular access.

Xeltis, a Netherlands-based developer of living cardiovascular implants, has received €12.5 million in additional funding from the European Innovation Council (EIC) Fund. This financial boost, combined with the Series D2 financing round announced in February 2023, brings the company's total funding to €44.5 million.
The funding will support the clinical development of Xeltis’ implants, notably the first-in-human (FIH) trial of its aXess vascular graft designed for patients with chronic kidney disease requiring hemodialysis. It will also support an ongoing pivotal trial for aXess, enrolling patients across Europe, and advance Xeltis’ coronary artery bypass graft program.

Endogenous Tissue Restoration

Xeltis' technology centers around its endogenous tissue restoration platform. This approach utilizes a polymer implant that facilitates the regeneration of the patient's own tissue. Over time, the polymer is absorbed, leaving behind a new, living, and durable vessel. The aXess implantable blood vessel, intended for hemodialysis vascular access, represents the company's most advanced product currently in clinical development.

Clinical Data

Earlier in the year, Xeltis presented 6-month data from the aXess-FIH study. Professor Matteo Tozzi, MD, presented the data at the 13th Congress of the Vascular Access Society in Porto, Portugal. These results underscore the potential of the aXess vascular graft in improving outcomes for patients requiring hemodialysis.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Xeltis Completes Enrollment in EU Pivotal Trial for aXess Vascular Access Conduit

Xeltis has completed enrollment in its EU pivotal trial for aXess, a restorative vascular access conduit, for adults with end-stage renal disease.
The trial, conducted across 22 centers in Europe, enrolled 120 patients to assess aXess's patency, safety, and performance for hemodialysis.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in Pivotal Trial

Xeltis' aXess, a synthetic vascular access device, has been granted Breakthrough Device designation by the FDA, expediting its path to market.
The pivotal trial, a prospective, single-arm, multi-center study, is evaluating the safety and performance of aXess in adults with end-stage renal disease needing dialysis.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in Pivotal Trial

Xeltis' aXess, a synthetic vascular access device, has been granted Breakthrough Device designation by the FDA, expediting its path to market through prioritized review and enhanced interaction with FDA experts.
The company has enrolled and treated the first patient in its US pivotal trial, a prospective, single-arm, multi-center study evaluating the safety and performance of aXess in adults with end-stage renal disease needing dialysis.

Xeltis' aXess Receives FDA Breakthrough Device Designation and Enrolls First Patient in US Pivotal Trial

Xeltis' aXess vascular access conduit receives FDA Breakthrough Device Designation, expediting its development and review for hemodialysis patients.
The designation acknowledges aXess' potential to offer a more effective vascular access option, reducing reinterventions and complications for dialysis patients.

Xeltis' aXess Receives FDA IDE Approval for US Pivotal Trial in Hemodialysis Vascular Access

Xeltis has received FDA approval for an Investigational Device Exemption (IDE) to initiate a US pivotal trial for its aXess vascular access conduit.
aXess is designed to create a new, living vessel for hemodialysis, combining the benefits of arteriovenous fistulas and grafts, potentially reducing complications.

Xeltis' aXess Conduit Shows Promise in Hemodialysis Vascular Access

Xeltis announced positive results from its aXess trials, evaluating a novel arteriovenous dialysis conduit for patients with end-stage renal disease.
The aXess conduit aims to create a long-term living vessel for hemodialysis, potentially reducing complications like infections and frequent reinterventions.

Xeltis' aXess Conduit Shows Promising 12-Month Results in Hemodialysis Access

Xeltis announced positive 12-month data from its first-in-human trial of aXess, a hemodialysis vascular conduit, presented at VEITHsymposium 2023.
The trial data showed 100% secondary patency and 78% primary assisted patency with no infections observed in 20 patients.

Xeltis Initiates Pivotal Trial for aXess Graft in Hemodialysis Patients

Xeltis has commenced a pivotal European clinical trial to assess the safety and efficacy of its aXess graft in patients with end-stage renal disease requiring hemodialysis.
The prospective, single-arm study aims to enroll 110 patients across up to 25 European centers, monitoring them over five years post-implantation.

Xeltis Initiates Pivotal Trial for aXess Hemodialysis Access Graft

Xeltis has begun a pivotal clinical trial for aXess, a novel restorative synthetic graft for hemodialysis access, with successful implantation in the first two patients.
The AXESS European pivotal trial will enroll 110 patients across up to 25 centers in Europe to assess the safety and performance of aXess over five years.

Xeltis' Axess Graft Shows Promising Early Results in Hemodialysis Access

Xeltis announced positive preliminary data from the AXESS trial, a first-in-human study of their Axess restorative hemodialysis access graft.
The Axess device demonstrated 100% cumulative primary and secondary patency with an average follow-up of 5.8 months in the initial study.

Reference News

[1]
Xeltis' aXess Vascular Graft Development Receives Funding From European ...
evtoday.com · Aug 14, 2023

Xeltis secured €12.5M from EIC Fund, totaling €44.5M raised. Funds will advance clinical trials for aXess vascular graft...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy